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Abstract: Currently, changes in metabolic fluxes following consumption of stable isotope-enriched
foods are usually limited to the analysis of postprandial kinetics of glucose. Kinetic information
on a larger diversity of metabolites is often lacking, mainly due to the marginal percentage of
fully isotopically enriched plant material in the administered food product, and hence, an even
weaker 13C enrichment in downstream plasma metabolites. Therefore, we developed an analytical
workflow to determine weak 13C enrichments of diverse plasma metabolites with conventional gas
chromatography-mass spectrometry (GC-MS). The limit of quantification was increased by optimizing
(1) the metabolite extraction from plasma, (2) the GC-MS measurement, and (3) most importantly,
the computational data processing. We applied our workflow to study the catabolic dynamics of
13C-enriched wheat bread in three human subjects. For that purpose, we collected time-resolved
human plasma samples at 16 timepoints after the consumption of 13C-labeled bread and quantified
13C enrichment of 12 metabolites (glucose, lactate, alanine, glycine, serine, citrate, glutamate,
glutamine, valine, isoleucine, tyrosine, and threonine). Based on isotopomer specific analysis, we
were able to distinguish catabolic profiles of starch and protein hydrolysis. More generally, our study
highlights that conventional GC-MS equipment is sufficient to detect isotope traces below 1% if an
appropriate data processing is integrated.
Keywords: GC-MS; stable isotope labeling; mass isotopomer distribution (MID); plasma; nutrition
1. Introduction
In the field of nutrition, the application of high-throughput metabolomics technologies has
increased remarkably over the past decade. The great potential of this technique was especially
recognized for biomarker discovery and dietary intervention studies [1]. Numerous examples illustrate
that postprandial metabolomics data from body fluids, such as urine, plasma, etc., contribute to a better
understanding of the consequences of a dietary intervention on metabolism [2–6]. Metabolomics data
capture a snapshot of the metabolic state of any investigated biological system by providing
information on absolute or relative metabolite levels at a distinct time point [2]. These data enable
a rather static view on the investigated system, but do not allow for the drawing of conclusions on
metabolite turnover or metabolic fluxes [7,8]. In this context, stable isotope labeling and time-resolved
sampling are effective tools to capture dynamic flux information of the system of interest [7,8].
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Several studies have demonstrated the potential of stable isotope labeling to elucidate the
dynamics of human central carbon metabolism [7,9–11]. To specifically determine the kinetics
of glucose turnover as a response to a nutritional intervention, sophisticated methods have been
developed. The application of dual label stable isotope techniques, for which subjects receive a
primed-continuous infusion of a stable isotope tracer (D-[6,6-2H2]glucose solution) and consume a
second tracer orally (e.g., 13C-labeled plant-based food product) followed by time-resolved blood
sampling, is a common method applied in nutritional research [12–15]. For some applications,
this methodology can further be extended by a third tracer to enhance the accuracy of rate
determination [15,16]. However, all these methods have two major limitations: first, they are
focused on glucose only and do not provide kinetic information on other plasma metabolites.
Although glucose is probably the most important metabolite to look at, the kinetic parameters of other
postprandial plasma metabolites, such as the glucose-derived metabolite lactate, the tricarboxylic acid
(TCA) cycle metabolite citrate, or amino acids like alanine or glutamate, are of similar importance.
Dynamic information about these metabolites allows for the study of metabolic fluxes in metabolic
pathways further downstream of glucose in response to an intervention. Similar analyses have already
been applied to study protein utilization [17] or synthesis [18], and postprandial lipid metabolism [19].
The second limitation is the high costs and efforts to produce the required stable isotope tracers [20].
While 13C-labeled substrates like glucose or glutamine are readily available, the production of labeled
food products, like wheat flour, is extremely intricate. U13C-wheat plants require the same growth
conditions as their regular counterparts, except that they have to be cultivated in a saturated 13CO2
atmosphere. As a result, all wheat flour components, such as starch (~63–72%) and wheat protein
(~12%), will be fully 13C-enriched [7,21,22]. To keep such analyses cost-effective, the amount of
tracer used in an experimental setup is kept at the required minimum, and does not normally
exceed 2% of isotopically enriched food product. Although the amount of uniformly labeled (M6)
glucose isotopologues is still above 1%, and thus detectable with routine GC-MS setups, enrichment
in metabolites further downstream are diluted with endogenous unlabeled compounds, typically
producing enrichments in the range of 0.01–1.00%.
Typically, the 13C enrichment is quantified in the form of mass isotopomer distributions
(MIDs). However, during GC-MS measurement, not only the 13C labeling introduced by e.g.,
the consumption of isotope-enriched food products, but also naturally occurring isotopes are detected.
Thus, the detected signal intensities need to be corrected to extract the 13C labeling of added by the
tracer. In a targeted approach, as presented here, a correction matrix can be constructed based on the
sum formula of the fully derivatized ion fragment [23]. The correction accounts for naturally occurring
isotopes in the target fragment including the attached atoms of the derivatization agent.
Taken together, the administration of stable isotope-enriched food products, in which
macronutrients like starch and protein are fully 13C-labeled, enclose the potential to trace kinetics of
many metabolites of central carbon metabolism [21]. The major challenge, thereby, is the accurate
determination of isotopic 13C enrichment below 1% in plasma metabolites by using standard GC-MS
analysis. To address this challenge, we combine routine selected ion monitoring (SIM)-based GC-MS
analysis with a specific mathematical data processing to accurately quantify 13C-isotopic enrichment
patterns and retain information on the distribution of all mass isotopomers for ultra-low enriched
metabolites. The leading advantage of our approach is that it can be performed on standard GC-single
quadrupole MS instruments that are present in many labs.
For this study, we selected polar target metabolites from three substance classes, namely organic
acids, amino acids, and sugars. Glycolytic activity is covered by the metabolites glucose, pyruvate,
and lactate, whereas the TCA cycle is represented by citrate, α-ketoglutarate, succinate, fumarate,
and malate. In addition, we further included several non-essential amino acids, such as alanine, glycine,
serine, glutamate, and glutamine, and some essential amino acids, like valine, leucine, isoleucine,
and tyrosine, in our workflow. We also target ketone body metabolism with 3-hydroxybutyrate,
and finally, the sugar alcohol erythritol, which has recently been linked to weight gain [24].
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Our analytical workflow comprises three separate stages: metabolite extraction, GC-MS
measurement, and data analysis. To optimally separate the target metabolites from the plasma matrix,
we decided for a liquid–liquid extraction (LLE) using a solvent/water mixture. The highest extraction
yield will be obtained if non-covalent bonds between protein and metabolites break, plasma proteins
are precipitated, and the target metabolites are highly soluble in the extraction fluid [25]. For this
reason, we tested several LLE protocols to identify the most suitable protocol for our workflow. In the
second stage, the GC-MS measurement, we aimed for a short run time to enable a high-throughput
performance, and at the same time, maintain a sufficient chromatographic separation. Due to the
particular importance of data processing in this workflow, we extended our MetaboliteDetector
software package accordingly [26].
2. Results
We herein describe the optimization of the analytical procedure and a data analysis approach
to generate accurate and highly reproducible mass isotopomer distributions (MIDs) for weakly
13C-enriched metabolites in human plasma.
The applied optimization strategy can be divided into three stages: (I) the plasma extraction
method, (II) the gas chromatography, and (III) the data analysis using MetaboliteDetector [26].
We evaluated our workflow on defined dilutions of 13C-enriched metabolites in human plasma,
and determined reproducibility, accuracy, and detection limits in this matrix. The applicability of
the workflow was further demonstrated on time-resolved postprandial human plasma samples from
three subjects that consumed 13C-enriched wheat bread (2% of U13C wheat flour) generated in the
course of a nutritional intervention study [27].
2.1. Optimization of Metabolite Extraction from Plasma
To optimize the extraction yield of all target metabolites, we tested seven different extraction
protocols established for plasma samples [25,28,29]. After GC-MS measurement of the derivatized
samples, signal intensities and the respective standard deviations of the target metabolites were
determined (n = 3). The signal intensities of all target metabolites were summed, and the average
standard deviation of all replicates was calculated to compare the extraction efficiency of the selected
protocols (Figure 1a,b). Using protocol E (methanol/water mixture, 5:1, v/v), the summed signal
intensity was increased by 25%, while the coefficient of variation over all target metabolites was
decreased by 50% when compared to protocol G (methanol/water mixture, 8:1, v/v). Based on
substance classes as shown in Supplementary Materials Figure S1, extraction protocol E primarily
increased the extraction yield for amino acids, while the extraction yield obtained for organic acids
and sugars was only slightly increased. For all substance classes, the relative average standard
deviations remained small, indicating a robust extraction procedure. Compared to protocol G, protocol
E has a higher water content, which leads to increased solubility of polar target metabolites and
reduced non-covalent protein–metabolite binding, which results in a higher metabolite recovery [25,28].
Although extraction yields significantly increased when using protocol E instead of G, due to the
increased water content, less proteins may have been precipitated in protocol E. Incomplete protein
precipitation could lead to enzymatic metabolite conversion, thereby falsifying the outcome. On the
other hand, when metabolite–protein binding occurs, metabolites are trapped and removed during
protein precipitation [30]. To estimate whether a higher water content might cause incomplete
protein precipitation, we performed an SDS-PAGE analysis of the plasma extracts, and determined
the respective protein concentrations, which are depicted in Figure 1c,d. As expected, the protein
concentration in extract E was about 5-fold higher (600 µg/mL) compared to the reference method G
(120 µg/mL). However, protein concentrations in plasma are between 80 mg/mL and 100 mg/mL,
which means that we precipitated 99.3% of all proteins with protocol E, and 99.8% with protocol G.
Lowering metabolite–protein binding by increasing the water content (protocol E) is beneficial for
metabolite recovery, especially for amino acid recovery when compared to protocol G, where protein
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precipitation is slightly more complete. Therefore, protocol E represents the best compromise, and we
selected it for our analytical workflow.
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Figure 1. Optimization of the metabolite extraction protocol from plasma—(a) Summed sample signal 
intensity (peak area) of all target metabolites; (b) relative average standard deviation of all target 
metabolites in relation to respective summed signal; (c) SDS-PAGE and Coomassie staining of plasma 
extracts; (d) protein concentration of plasma extracts (A—isopropanol/acetone 1:2, B—methanol, C—
acetonitrile/H2O, 3:1, D—H2O/acetonitrile/methanol 1:2:2, E—methanol/H2O, 5:1, F—acetonitrile, G—
methanol/H2O, 8:1), (blue—optimized, red—reference method). 
2.2. Optimization of the Gas Chromatography Measurements 
A gas chromatographic method suitable for high throughput is primarily characterized by a 
short run time. Moreover, resolution and separation of the targeted metabolites are presupposed. 
Applying the concept of fast GC by substituting the often (for metabolomics purposes) used column 
(length: 30 m, diameter, 0.25 mm, film thickness: 0.25 µm) with a shorter column with decreased 
diameter and film thickness (length: 20 m, diameter, 0.18 mm, film thickness: 0.18 µm) results in a 
shorter elution time per peak. As shown in Figure 2, the run time of the established GC method was 
reduced by 40%, from 26 min to 15 min. Figure 2a illustrates that the separation length of the 26 min 
method was not efficiently used, because all our target metabolites eluted at retention times between 
3 min and 14 min. By adapting the temperature profile, the chromatographic capacity is fully utilized, 
and the resolution and separation of our target metabolites is improved. (Figure 2b). 
Figure 1. Optimization of the metabolite extraction protocol from plasma—(a) Summed sample
signal intensity (peak area) of all target metabolites; (b) relative average standard deviation of
all target metabolites in relation to respective summed signal; (c) SDS-PAGE and Coomassie
staining of plasma extracts; (d) protein concentration of plasma extracts (A—isopropanol/acetone 1:2,
B—methanol, C—acetonitrile/H2O, 3:1, D—H2O/acetonitrile/methanol 1:2:2, E—methanol/H2O, 5:1,
F—acetonitrile, G—methanol/H2O, 8:1), (blue—optimized, red—reference method).
2.2. Optimization of the Gas Chromatography Measurements
A gas chromatographic method suitable for high throughput is primarily characterized by a
short run time. Moreover, resolution and separation of the targeted metabolites are presupposed.
Applying the concept of fast GC by substituting the often (for metabolomics purposes) used column
(length: 30 m, diameter, 0.25 mm, film thickness: 0.25 µm) with a shorter column with decreased
diameter and film thickness (length: 20 m, diameter, 0.18 mm, film thickness: 0.18 µm) results in a
shorter elution time per peak. As shown in Figure 2, the run time of the established GC method was
reduced by 40%, from 26 min to 15 min. Figure 2a illustrates that the separation length of the 26 min
method was not efficiently used, because all our target metabolites eluted at retention times between
3 min and 14 min. By adapting the temperature profile, the chromatographic capacity is fully utilized,
and the resolution and separation of our target metabolites is improved. (Figure 2b).
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superimposition with mass spectrometric noise at low intensities, the integration of such peaks can 
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Figure 2. Optimization of the gas chromatography method—(a) GC column of 30 m in length, inner
diameter of 0.25 mm and film thickness of 0.25 µm results in a run time of 26 min; (b) GC column of
20 m in length, inner diameter of 0.18 mm, and film thickness of 0.18 µm results in a run time of 15 min.
2.3. Optimization of Data Analysis with Metabolite Detector
When determining 13C enrichments below 1%, precise algorithms for the MID calculation are
required. The basis of an exact MID determination is the accurate integration of peak areas (ion
current/time) for all target ions. While the intensities of the most abundant, monoisotopic fragment
peak are usually far above the detection limit, intensities of isotopic peaks are, in many cases, low and
close to the detection limit, especially for faintly enriched compounds. Due to the superimposition
with mass spectrometric noise at low intensities, the integration of such peaks can be impaired,
and hinder MID determination for weakly enriched metabolites. The accuracy of peak integration
can be significantly improved when mathematically fitting areas of peaks with lower abundance to
the shape of a model peak obtained from peaks of the same compound, but with a higher intensity.
In Figure 3a,b, this behavior is demonstrated using the mass spectrum of glutamate as an example.
Since the peak shape of the monoisotopic fragment (M + 0) is identical to those of the respective
isotopic peaks (M + 1–M + 5), a model peak can be constructed based on the higher quality peak shapes.
This model peak is then used to correct the peak integrals of l wer quality peaks. To evaluate the benefit
of the applied correction, we compared MIDs obtai ed for different concentrations (40 µM and 200 µM),
and 13C enrichments (0.10% and 0.01%) of glutamate sing d fined mixtures of non-labeled and fully
labeled glutamate (U13C-glutamate) in aque s solution. Data analysis was rformed with and
without the application f the model peak correction step (Figure 3c). Without model peak correction,
we calculat d an incr ased M5 fraction of 0.15% instead of the expected 13C enrichment f 0.1% t high
metabolite c centration (200 µM). At l glutamate concentrations (40 µM) and for lower enrichment
(0.01%), M5 abundance was drastically overestimat d at 0.55%. By contrast, if the mod l peak
correctio was pplied, th obtained M5 abu dance matched the expected enrichments accurate y at
high glutamate o centratio s. At low glutamate concentr tion and 0.10% 13C enrichment, the labeling
was slightly overestimated, and we calculate an M5 abundance of 0.14% instead of 0.1%. At lower
13C enrichme t (0.01%) and at low glutamate concentrations, the accuracy for MID determination
further decreased. Even if model peak correction is applied, M5 abunda ce is highly overestimated
(0.083% instead of 0.01%) when the signal of isotopic is close to the limit of detection. Although the
results were still more accurate than without the application of the model peak, when both enrichment
and metabolite level are low, MID determination is prone to error, and the application of our workflow
reaches a limit. In conclusion, we demonstrated that the model peak correction significantly improved
the accuracy of MID determination, especially when the target metabolites were low in 13C enrichment
and/or concentration.
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(Glutamate_3TMS); (b) the peak shape of the monoisotopic peak of glutamate (M0—m/z 348) is of 
high quality, and therefore used for peak shape correction of the low intensity isotopic peaks, like the 
5-times labeled derivative (M5—m/z 353); (c) comparison of the mass isotopomer distributions (MIDs) 
for 0.10 and 0.01%. 13C-enriched glutamate at high (200 µM) and low (40 µM) concentration, calculated 
with (gray) and without (red) model peak correction. 
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To evaluate the potential of our workflow for plasma metabolites, we generated plasma samples 
with defined isotopic enrichments. For that purpose, we first incubated A549 lung cancer cells in the 
presence of U13C-glucose and -glutamine, and extracted intracellular metabolites to obtain a mixture 
of many labeled metabolites. We then diluted this labeled extract in (non-labeled) plasma to obtain 
decreasing 13C isotopic enrichments (1:10, 1:100, 1:200, 1:500, and 1:1000). We applied our workflow 
and determined MIDs for all selected target metabolites, with and without model peak correction. 
Out of the 25 target metabolites, 9 metabolites were included in the validation (Table 1). Based on the 
determined enrichments at dilution 1:10, we projected the expected 13C enrichment for all the other 
dilutions. As an example, we demonstrated our analysis for the M5 isotopologue of glutamine. The 
determined, as well as the projected enrichments for the dilutions 1:100, 1:200, 1:500, and 1:1000, are 
depicted in Figure 4. As expected, the model peak correction significantly improved the MID 
determination for faintly enriched M5 glutamine. With enabled model peak correction, the minimal 
determined enrichment for glutamine M5 was 0.026%, with an acceptable accuracy (0.002%, 
injections of same sample, n = 3) and reproducibility (0.014%, sample extraction, n = 3). Without this 
correction, we could not determine any 13C enrichment below 0.32% (accuracy = 0.15%, 
reproducibility = 0.19%). Next, we compared projected and determined fraction of M5 glutamine for 
all enrichments (Figure 4b), and performed a linear regression of projected and determined 
enrichments. The model peak correction increased the correlation between expected and observed 
Figure 3. Model peak correction shown for glutamate using MetaboliteDetector—(a) Gas
chromatographic peak and respective mass spectrum of the glutamate MSTFA derivative
(Glutamate_3TMS); (b) the peak shape of the monoisotopic peak of glutamate (M0—m/z 348) is
of high quality, and therefore used for peak shape correction of the l w int nsity so opic peaks, like
the 5-times labeled derivative (M5—m/z 353); (c) comparison of the mass isotopomer distributions
(MIDs) for 0.10 0.01%. 13C-enriched glutamate at high (200 µM) and low (40 µM) concentration,
calculated with (gray) and without (red) model peak correction.
2.4. Quantification of 13C Enrichment in Plasma
To evaluate the potential of our workflow for plasma metabolites, we generated plasma samples
with defined isotopic enrichments. For that purpose, we first incubated A549 lung cancer cells in
the presence of U13C-glucose and -glutamine, and extracted intracellular metabolites to obtain a
mixture of many labeled met bolites. We then diluted this labeled extract in (non-labeled) plasma
to obtain decreasin 13C isot pic enrichment (1:10, 1:100, 1:200, 1:500, and 1:1000). W applied our
workflow and determined MIDs f r all selected target metabolites, with and without m del peak
correction. Out of the 25 target metabolites, 9 metabolites were included in the validation (Table 1).
Based on the determined enrichments at dilution 1:10, we projected the expected 13C enrichment for
all the other dilutions. As an example, we demonstrated our analysis for the M5 isotopologue of
glutamine. The determined, as well as the projected enrichments for the dilutions 1:100, 1:200, 1:500,
and 1:1000, are depicted in Figure 4. As expected, the model peak correction significantly improved
the MID determination for faintly enriched M5 glutamine. With enabled model peak correction,
the minimal determined enrichm nt for glutamine M5 was 0.026%, with an accept ble accuracy
(0.002%, i jectio s of sam sample, n = 3) and reproducibility (0.014%, sample extraction, n = 3).
Without t is correction, we could not determine any 13C enrichment below 0.32% (accuracy = 0.15%,
reproducibility = 0.19%). Next, we compared projected and determined fraction of M5 glutamine for all
enrichments (Figure 4b), and performed a linear regression of projected and determined enrichments.
The model peak correction increased the correlation between expected and observed values and, most
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importantly, revealed a regression line slope of 0.95 instead of 1.23, without correction. A slope of
1 would represent a perfect agreement of projected and determined enrichments. To extend these
observations to further metabolites, we calculated the correlation coefficient and the slope for all
13C-enriched metabolites, and summarized all results in Table 1. The model peak correction increased
the limit of enrichment quantification by one order of magnitude for almost all metabolites. In addition,
the accuracy and reproducibility are higher, which is reflected by slopes of the regression lines closer to
1. Taken together, the application of a model peak for peak integration improves MID determination,
especially for isotopologues with a low frequency, and turned out to be essential for isotopologues
with fractions below 0.5%.
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2.5. In Vivo Metabolism of Fully 13C-Labeled Wheat Flour 
Finally, we set out to apply the enhanced workflow to study the metabolism of labeled wheat 
flour in human subjects. For this, we blended 2% of fully 13C-labeled flour with 98% unlabeled flour, 
and used this blend for the preparation of an Indian chapati bread. Three healthy male subjects (S1, 
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detected 13C labeling in 12 out of 25 target metabolites (Figure 5 and Supplementary Materials Figure 
S1), and could trace the metabolism of the wheat compounds to metabolites located further 
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about starch and protein hydrolysis can be obtained. We observed substantial differences between 
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M5 abundance, with (gray) and without (red) model peak correction for linear regression analysis.
2.5. In Vivo Metabolism of Fully 13C-Labeled
Finally, we set out to ap ly the nhanced workfl t t t e etabolism of lab led wheat
flour in human subjects. For this, we blended 2 of f lly C-labeled flour with 98% unlabeled flour,
and used this blend for the preparation of an Indian chapati bread. Three healthy male subjects
(S1, S2, S3) then ingested this bread, and their plasma was sampled time-resolved over a period of
3 h. Already after 15 min, we started to observe M6 glucose isotopologues, reaching a maximum of
1.5% of total glucose after 150–200 min. Although the enrichment of plasma glucose was below 2%,
we detected 13C labeling in 12 out of 25 target metabolites (Figure 5 and Supplementary Materials
Figure S1), and could trace the metabolism of the wheat compounds to metabolites located further
downstream of glucose. The enrichment kinetics of lactate and alanine were very similar, suggesting
a close metabolic coupling of these metabolites. Interestingly, we could also observe synthesis of
glutamate from wheat starch. The M2 isotopologue of this amino acid followed the kinetic of the
other glucose-derived metabolites, but the isotopic enrichment was further diluted by one order
of magnitude. In addition to M2 glutamate isotopologues, we observed significant fractions of M5
isotopologues of glutamate and glutamine. These isotopologues cannot be derived from glucose,
and must therefore originate from wheat protein (gluten). This was also s orted by the different
kinetics of M5 glutamate and glutamine, compared to M2 (Figure 5 and Supplem ntary Materials
Figure S2). Based on the appearance kinetics of just these two isotopologues, detailed information about
starch and protei hydrolysis can be obtained. We observed substantial differences between starch-(M2)
and protein-derived (M5) glutamate, the main difference being that protein-derived glutamate reaches
its maximum earlier, compared to starch-d rived glutamate. Moreover, we found clear differenc s in
the isotope appearance kinetic of the three subjects. While the kinetics in subject 1 and 3 were very
similar, all investigated metabolites were labeled later in subject 2. This observation indicates a distinct
“between subject” variability in the digestion and metabolism of wheat bread. To summarize, despite
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the very low enrichment of 0.3% for M2 glutamate and 0.1% for M5 glutamate, we could successfully
trace metabolism of wheat-derived starch and gluten down to this amino acid. Based on time resolved
sampling, we observed differences between starch and protein hydrolysis. Due to the high accuracy
and sensitivity of presented methodology, we could even determine between-subject variation for
both processes.
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subject 1 (S1), subject 2 (S2), and subject 3 (S3)—(a) Wheat bread with 2% of 13C-labeled
wheat flour is composed of 13C-labeled starch and 13C-la el d prot in. The labeled hydrolysis
products, lab led glucose (black) and fre labeled amino acids (r d) enter metabolism; and
(b) enrichment patterns of the plasma metabolites glucose (M6), lactate (M3), citrate (M2),
alanine (M3), glutamate (M2) and glutamate (M5) can be measured by GC-MS. Lac—lactate,
Ala—alanine, OxAc—oxaloacetate, Cit—citrate, aKG—alpha-ketoglutarate, Glu—glutamate,
LD—lactate dehydrogenase, PDH—pyruvate dehydrogenase, CS—citrate synthase, Aco—aconitase,
IDH—isocitrate dehydrogenase, OGDC—oxoglutarate dehydrogenase complex.
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Table 1. MID calculation obtained from labeled A549 cell extract diluted in plasma (1:1000, 1:500, 1:200, 1:100, and 1:10) of the original 13C enrichment) with model
peak correction and without model peak correction; determination of accuracy (3 injections) and reproducibility (standard deviation, 3 extractions) of minimal MI
abundance, slope and R2 determined by regression analysis.
Metabolite
Concentration
Range (µM) MI
Model Peak No Model Peak
Min MI
Abundance (%)
Accuracy
(n = 3)
Reproducibility
(n = 3)/Stdev Slope R
2 Min MI
Abundance (%)
Accuracy
(n = 3)
Reproducibility
(n = 3)/Stdev Slope R
2
Serine 87.9–96.2 M3 0.0207 0.0263 0.0054 0.76 0.98 0.5800 0.0728 0.0400 0.27 0.81
Alanine 302.0–330.0 M3 0.0165 0.0059 0.0089 0.82 0.99 0.8950 0.0565 0.1293 0.18 0.65
Lactate 1540–1620 M3 0.0054 0.0022 0.0013 1.02 1 0.0410 0.0062 0.0031 0.97 1
Erythronate 15.0–16.0 M4 0.2317 no data 0.1545 1.01 0.99 4.7448 1.0821 0.3720 0.48 0.82
Fumarate 2.1–2.3 M4 0.4698 2.4931 0.1227 0.9 0.92 5.2324 0.3983 1.8185 0.59 0.96
Glutamine 409.8–469.3 M5 0.0260 0.0022 0.0135 0.95 1 0.3162 0.1518 0.1856 1.22 1
Glucose 6330–6631 M6 0.2337 no data 0.0167 0.6 0.98 0.8812 no data 0.0471 0.34 0.9
Glutamate 540.1–657.0 M5 0.0293 0.0015 0.0038 1 1 0.1024 0.0094 0.0095 0.98 1
Succinate 9.6–10.4 M4 0.1001 0.0831 0.0639 0.73 0.95 1.8842 0.1708 0.3157 0.3 0.95
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3. Discussion
Incorporating metabolic flux analysis into metabolomics experiments expands static snapshot
information on relative differences in metabolite pool sizes to dynamic information on metabolic
regulation. So far, stable isotope-assisted metabolomics (SIAM) has been mainly applied to elucidate
biochemical pathways in cellular systems and animals [7,31–33]. In human nutrition, metabolic flux
analysis has, in general, been limited to the kinetics of glucose, mainly because of the high costs
for stable isotope tracers. Due to the high dilution of stable isotope tracers in human metabolism
in vivo, isotopic enrichment in target metabolites is very low, and in most cases, far below natural
isotope enrichment. To enable SIAM in human nutrition, a robust, cost-efficient and sensitive method
for the quantification of isotope incorporation is needed. Therefore, we developed the presented
SIAM workflow.
A popular technology for the determination of low isotope enrichment is gas chromatography-
combustion-isotope ratio mass spectrometry (GC-C-IRMS), due to its higher sensitivity, precision,
and accuracy, compared to routine GC-MS [31,33]. Contrarily, the main advantages of GC-MS are
the increased applicability and affordability, as well as the possibility to obtain more informative
mass isotopomer distributions (MIDs), as compared to the isotope ratios of combusted metabolites
obtained by GC-C-IRMS [34]. The additional value of MID data when compared to isotope ratios
is demonstrated in Figure 5 for glutamate. Since this metabolite is generated either from starch or
protein hydrolysis, distinct isotopologues are thereby produced (M2 vs M5), and information on starch
and protein hydrolysis can be obtained by just measuring one metabolite. This information would be
lost in case of GC-C-IRMS analysis. In addition, GC-MS measurements allow for higher throughput
when compared to GC-C-IRMS [33], which is especially important in large-scale time-resolved dietary
intervention studies with hundreds or thousands of samples.
To overcome the GC-MS related sensitivity issues, we put a strong emphasis on the optimization
of the analytical method, as well as the computational data processing. Initially, we compiled a list of
target metabolites involved in central carbon metabolites. The advantage of a targeted approach is
obvious for this application, as the chemical properties of the metabolites are known, which facilitates
the selection of applicable extraction and mass spectrometric methods [25]. For the extraction of
diverse compound classes, such as sugars, organic acids, and amino acids from plasma, we suggest
applying an extraction fluid composed of methanol and water in a ratio 5:1. The increased polarity
compared to other mixtures (e.g., methanol/water, 8:1) reduces protein–metabolite binding, thereby
promoting higher extraction yields for polar metabolites.
We applied the concept of fast GC to reduce the measurement time, while maintaining and even
increasing the resolution and separation of the target metabolites [35]. According to this concept,
the run time of a GC measurement can be simply reduced by using a shorter column with reduced
inner diameter and film thickness. When reducing both the inner diameter and the film thickness,
the plate height, H, decreases according to the equation of Golay, which results in an increase in the
efficiency N and the chromatographic resolution Rs [35]. By using a 20 m column with an internal
diameter of 0.18 mm and a film thickness of 0.18 µm, we were able to reduce the run time by 40%,
while at the same time increasing the separation of our target metabolites.
Fitting low abundant isotopic peaks to the shape of higher abundant monoisotopic peaks has
proven successful in GC-MS based analysis [26,36,37]. We extended this practice to increase the quality
of MID determination. In our workflow, the peak shape correction increased the limit of isotopic
detection and quantification by one to two orders of magnitudes (Table 1). Especially when the
concentration of the target metabolite was in the lower range, MID calculation was highly improved
when the model peak correction was applied (Figure 3).
Previous studies involving isotopic enrichment below 1% were mainly focused on single or
a few target metabolites e.g., glucose [38], cholesterol in different species [34], or phenylalanine
and leucine in muscle protein synthesis [39]. We widened this scope by targeting 25 metabolites
of central carbon metabolism that are involved in different metabolic pathways, such as glycolysis,
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TCA cycle, and amino acid metabolism. Phosphorylated metabolites, like phosphoenolpyruvate
and various pentose phosphate pathway metabolites, e.g., glucose-6-phosphate, were not taken into
account, because these are not stably accumulating in blood [40]. By dissolving labeled cell extracts in
human plasma, we simulated low 13C enrichment in plasma metabolites, and were able to quantify
13C-enriched isotopologues of 9 out of 25 target metabolites, with the lowest enrichment being between
0.005% (lactate) and 0.5% (fumarate), with a reproducibility between 0.001% (lactate) and 0.12%
(fumarate) (Table 1). Due to the fact that we labeled the cells with U13C-glucose and -glutamine, not all
target metabolites get labeled. For example, the essential amino acids valine, leucine, and isoleucine
are not synthesized by these cells, and are thus not isotopically enriched, and could not be taken
into account for the validation. For a number of metabolites, including the TCA cycle intermediate
α-ketoglutarate and aspartate, no 13C isotopic enrichment was detected due to the combination of
strongly diluted enrichment and low metabolite concentrations [41,42]. Moreover, it was not possible to
reproducibly determine 13C isotopic enrichment for pyruvate, due to instability of the derivative [43].
For the M3 isotopologue of glucose, representing a marker for gluconeogenesis [44], the isotopic
enrichment was also too strongly diluted.
Taken together, our workflow allows for measuring the enrichment of several important metabolites
down to a sensitivity of 0.01%. Although we could significantly increase the overall sensitivity for MID
determination, we were not able detect isotopic enrichments as low as 0.0001–0.0005%, values which have
been reported for GC-C-IRMS [31,45].
To validate our workflow in a real case scenario, we applied it to analyze time-resolved plasma
samples from three different subjects who consumed wheat bread enriched with 2% fully labeled
wheat flour, and detected 13C labeling in 12 out of 25 target metabolites. We demonstrated that we
can trace two distinct and independent routes of flour catabolism, starch, and protein hydrolysis.
We were able to follow the dynamics of starch hydrolysis and that of further metabolites downstream
of glucose. Glucose M6 starts appearing and reaching a maximum after 150 min for subject 1
and 3, and after 250 min for subject 2. Depending on the metabolic distance, the maximum 13C
enrichment of downstream metabolites is delayed (lactate M3—170 min, alanine M3—200 min, citrate
M2—210 min, glutamate M2—210 min). On the other hand, appearance of fully labeled free amino
acids originating from protein (gluten) hydrolysis represented by glutamate M5 reaches maximal
13C enrichment already after 100 min. Similar results were obtained for M5 glutamine and M5
valine (Supplementary Figure S2). Based on this observation, we conclude that upon consumption
of wheat bread, protein hydrolysis is faster than starch hydrolysis. Moreover, we observed strong
“between-subject” differences in postprandial kinetics after bread ingestion, which could partly be
related to the gut microbiome [46].
4. Materials and Methods
4.1. Reagents and Materials
The reference compounds (sodium pyruvate, sodium lactate, citric acid monohydrate,
succinic acid, malic acid, fumaric acid, 2-hydroxybutyric acid, oxalic acid, 3-hydroxybutyric
acid, glycine, L-serine, L-valine, L-threonine, L-alanine, L-aspartic acid, L-glutamine, L-glutamic
acid, L-leucine, L-isoleucine, L-tyrosine, erythronate, meso-erythritol, α-ketoglutaric acid, glyceric
acid) were purchased from Sigma-Aldrich, Munich, Germany. U13C-Ribitol (CIL Inc., Tewksbury,
MA, USA), pentanedioic-d6-acid (C/D/N isotopes Inc., Quebec, QC, Canada), and norleucine
(Sigma-Aldrich, Munich, Germany) were used as internal standards during metabolite extraction.
U13C-Glutamate, U13C-glucose, and U13C-glutamine were purchased from CIL Inc., Tewksbury, MA,
USA. For metabolite extraction, high purity HPLC (or higher) grade solvents methanol, acetone,
isopropanol, and acetonitrile, and MQ water (18.2 M·cm, <3 ppb TOC) were used.
Metabolites 2018, 8, 15 12 of 18
4.2. Plasma Samples
The blood sampling was conducted according to the guidelines of “World Medical Associations,
Declaration of Helsinki—Ethical principles for medical research involving human subjects” and
registered at the Comité national d’éthique de recherché (CNER) under the project number 201107/02.
Plasma was produced from whole blood by centrifugation at 4 ◦C and 1600g for 10 min with
deceleration set to 1. The plasma was used for plasma extraction optimization as described in section
Metabolite extraction from plasma.
For the 13C-enrichment assay with labeled A549 extract, commercial plasma IPLA-N-50mL-K2EDTA
(Tebu-Bio, Offenbach, Germany) was used for dilution.
To evaluate the Applicability of the workflow on plasma from a nutritional intervention study, we
obtained plasma samples collected over a 360 min time frame from three subjects that consumed wheat
bread with 2% of the wheat flour substituted with fully 13C-labeled wheat flour [27].
4.3. Metabolite Extraction from Plasma
We tested seven different metabolite extraction protocols, as described in Table 2. All extraction
fluids (EF) were prepared in advance, and kept at −20 ◦C prior to extraction. For comparability
reasons, we used 20 µL of plasma for every extraction method and adapted the volume of the required
EF accordingly. Mixing was performed at 4 ◦C and 2000 rpm for 5 min, and centrifugation was done at
4 ◦C and 21,000g.
Table 2. Overview of tested metabolite extraction protocols from plasma A–G, summarizing the
composition of the extraction fluid (EF), the required volume, the duration of centrifugation, and the
transferred volume into the GC vial.
Identifier Extraction Fluid Volume EF (µL) Centrifugation (min) Volume Vial (µL)
A [27] Acetone/Isopropanol, 1:2 267 5 200
B [28] Methanol (MeOH) 60 15 56
C Acetonitrile (ACN)/H2O, 3:1 180 5 140
D H2O/MeOH/ACN, 1:2:2 180 5 140
E MeOH/H2O, 5:1 180 5 140
F ACN 77.5 20 68.25
G [24] MeOH/H2O mixture, 8:1 180 5 140
After pipetting the indicated volume of plasma extract into the GC vials, the samples were dried
overnight at −4 ◦C in a refrigerated vacuum concentrator (Labconco, Kansas City, MO, USA).
4.4. Coomassie Staining
To compare the amount of protein present in the different plasma extracts, proteins were separated
by SDS-PAGE on a 10% gel (10% Mini Protean® TGX™ Precast Protein Gels, 10-well, 30 µL, Bio-Rad,
Munich, Germany). To reduce the influence of the solvents on protein separation, 21 µL of each
extract were dried in a refrigerated vacuum concentrator, and redissolved in 27 µL 1× Laemmli buffer.
A voltage of 110 V for 1 h was applied. After protein separation, the gel was washed in MQ water for
1 h. The proteins were stained with Coomassie staining solution, composed of 2% Coomassie blue,
7.5% acetic acid, and 50% ethanol for 1 h. For destaining, the gel was transferred into a destaining
solution composed of 10% acetic acid and 40% methanol for 3 h, and the solution was exchanged
several times.
4.5. Protein Quantification
Protein concentrations were determined using the Pierce BCA Protein Assay Kit (23225,
Thermo Fisher Scientific, Waltham, MA, USA), according to manufacturer’s instructions.
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4.6. 13C-Enrichment Assay of Glutamate
Different concentrations (low: 40 µM and high: 200 µM) and 13C enrichments (0.10% and 0.01%)
of glutamate were adjusted by mixing 1 mM solutions of non-labeled glutamate, and fully labeled
U13C-glutamate in water. The targeted concentrations and enrichments were extracted in accordance
with extraction protocol E, and measured by GC-MS.
4.7. 13C-Enrichment Assay of 13C-Labeled Cell Extract
Human A549 lung cancer cells (4 × 106) were seeded in a 10 cm Petri dish in D5030 medium
supplemented with 25 mM U13C-glucose and 4 mM U13C-glutamine, and incubated at 37 ◦C and 5%
CO2. After 28 h, intracellular metabolites were extracted according to Sapcariu et al. [47]. Briefly, cells
were washed with 0.9% NaCl. Ice-cold methanol (2.7 mL) and 2.7 mL cold H2O (4 ◦C) were added
to the cells to quench the metabolism. The methanol–water mixture was added into 3 mL of ice-cold
chloroform. The mixture was shaken at 4 ◦C and 1400 rpm for 20 min, and centrifuged at 4 ◦C
and 17,000g for 10 min. The upper phase containing the polar metabolites was separated and
used for further analyses. To investigate low 13C-enrichment of plasma metabolites, 20 µL of cell
extract was dried in a 1.5 mL reaction tube at 4 ◦C in a refrigerated vacuum centrifuge. The dried
metabolites were dissolved in 20 µL of water (100%), and 180 µL of commercially available plasma
(IPLA-N-50mL-K2EDTA) was added to dilute the 13C-enrichment by 1:10. By further diluting with
non-labeled plasma, we obtained the dilutions of 1:100, 1:200, 1:500, and 1:1000 of the original
13C-enrichment. The samples were extracted according to extraction protocol E, and measured
by GC-MS.
4.8. Metabolite Extraction of Plasma Samples from a Nutritional Intervention Study
To evaluate the applicability of the developed workflow, protocol E was applied for the extraction
of the plasma samples of a nutritional intervention study [26].
4.9. Metabolite Derivatization and GC-MS Measurement
Derivatization. Online metabolite derivatization was performed using a Gerstel MPS. Dried polar
metabolites were dissolved in 15 µL of 2% methoxyamine hydrochloride in pyridine at 40 ◦C under
shaking. After 90 min, an equal volume of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA)
was added, and held for 30 min at 40 ◦C under continuous shaking.
Established GC-MS measurement. Sample (1 µL) was injected into an SSL injector at 270 ◦C in
splitless mode. GC-MS analysis was performed using an Agilent 7890A GC equipped with a 30 m
DB-35MS + 5 m Duraguard capillary column (0.25 mm inner diameter, 0.25 µm film thickness).
Helium was used as carrier gas at a flow rate of 1.0 mL/min. The GC oven temperature was held at
90 ◦C for 1 min, subsequently increased to 300 ◦C at 10 ◦C/min, and held at that temperature for 5 min,
resulting in a total run time of 26 min per sample.
Optimized GC-MS measurement. Sample (1 µL) was injected into an SSL injector at 270 ◦C in
split mode (10:1). GC-MS analysis was performed using an Agilent 7890A GC equipped with a
20 m DB-5MS capillary column (0.18 mm inner diameter, 0.18 µm film thickness) (121-3822, Agilent,
Santa, Clara, CA, USA). Helium was used as carrier gas at a flow rate of 1.0 mL/min. The GC oven
temperature was held at 90 ◦C for 0.5 min, and increased to 220 ◦C at a rate of 13 ◦C/min. Reaching a
temperature of 220 ◦C, the rate was increased to 325 ◦C at a rate of 100 ◦C/min, and the temperature
was held for 3.5 min. This temperature profile results in a run time of 15 min per sample.
Mass Spectrometry—Tuning. According to the supplier’s instruction, an automated tuning routine
was applied every 150 injections.
Mass Spectrometry—SCAN mode. The GC was connected to an Agilent 5975C inert XL MSD.
The transfer line temperature was set to 280 ◦C, and the MSD was operating under electron ionization
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at 70 eV. The MS source was held at 230 ◦C and the quadrupole at 150 ◦C. Full scan mass spectra were
acquired from m/z 70 to m/z 800 at a scan rate of 5.2 scans/s.
Mass Spectrometry—SIM mode. For MID calculation, GC-MS measurements of the metabolites of
interest were additionally performed in selected ion monitoring (SIM) mode. The detailed settings
for each metabolite are summarized in Table 3. Correction for naturally occurring isotopes was done
based on the sum formula of each derivative. Table 4 contains the settings for the internal standards
used for normalization in batch quantification. For every substance class, one internal standard was
selected (norleucine—amino acids, pentanedioic-acid-d6—organic acids, U13C-ribitol—sugars and
sugar derivatives).
Table 3. Settings applied in selected ion monitoring (SIM) mode for the detection of the target metabolites.
Metabolite Derivatization Dwell Time (ms) Fragment Sum Formula m/z
Pyruvate 1MeOX 1TMS 10 M-15 C6H12O3NSi 174.1
Lactate 2TMS 15 M-15 C8H19O3Si2 219.1
Alanine 2TMS 15 M-15 C8H20O2NSi2 218.1
2-Hydroxybutyrate 2TMS 15 M-15 C9H21O3Si2 233.1
Oxalate 2TMS 15 M-15 C7H15O4Si2 219.1
3-Hydroxybutyrate 2TMS 20 M-15 C9H21O3Si2 233.1
Valine 2TMS 15 M-15 C10H24O2NSi2 246.1
Leucine 2TMS 15 M-15 C11H26O2NSi2 260.2
Isoleucine 2TMS 15 M-15 C11H26O2NSi2 260.1
Glycine 3TMS 20 M-15 C10H26O2NSi3 276.1
Succinate 2TMS 15 M-15 C9H19O4Si2 247.1
Glycerate 3TMS 15 M-30 C10H24O4Si3 292.1
Fumarate 2TMS 15 M-15 C9H17O4Si2 245.1
Serine 3TMS 20 M-15 C11H28O3NSi3 306.1
Threonine 3TMS 15 M-15 C12H30O3NSi3 320.2
Malate 3TMS 15 M-15 C12H27O5Si3 335.1
Erythritol 4TMS 20 M-90 C10H24O4Si4 320.2
Aspartate 3TMS 15 M-15 C12H28O4NSi3 334.1
Erythronate 4TMS 20 M-15 C15H37O5Si4 409.2
α-Ketoglutarate 1MeOX 2TMS 10 M-15 C11H22O5NSi2 304.1
Glutamate 3TMS 15 M-15 C13H30O4NSi3 348.1
Glutamine 3TMS 15 M-15 C13H31O3N2Si3 347.2
Citrate 4TMS 15 M-15 C17H37O7Si4 465.2
Glucose 1MeOX 5TMS 15 M-15 C21H52O6NSi5 554.3
Tyrosine 3TMS 10 M-15 C17H32O3NSi3 382.2
Table 4. Settings applied in SIM mode for internal standards.
Internal Standard (IS) Derivatization Ions
Norleucine 2TMS 158.1, 232.1, 260.1
Pentanedioic-acid-d6 2TMS 206.1, 239.1, 267.1
U13C-Ribitol 2TMS 220.1, 310.1, 323.2
4.10. Data Processing
Deconvolution of mass spectra, peak picking, integration, and retention index calibration were
performed using the MetaboliteDetector software [26]. Compounds were identified using an in-house
mass spectral library. The following deconvolution settings were applied for SCAN data: peak
threshold: 5; minimum peak height: 5; bins per scan: 10; deconvolution width: 5 scans; no baseline
adjustment; minimum 15 peaks per spectrum; no minimum required base peak intensity. Retention
index calibration was based on an C10–C40 even n-alkane mixture (68281, Sigma-Aldrich, Munich,
Germany). For SIM data, the following setting were applied: peak threshold: 1; minimum peak
height: 1; bins per scan: 10; deconvolution width: 7 scans; no baseline adjustment; minimum 2
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peaks per spectrum; no minimum required base peak intensity. Retention index calibration was
based on retention time. MIDs were calculated using MetaboliteDetector’s MID wizard, and relative
quantification was done using the batch quantification function.
5. Conclusions
The application of our developed workflow enables the accurate determination of 13C enrichment
below 1% in up to 25 plasma metabolites with conventional GC-MS instruments. By taking advantage
of this powerful method, insights into the dynamics of digestive processes, like starch and protein
hydrolysis, could be revealed. Moreover, conclusions on metabolic fluxes and pathway regulations
can be drawn.
Supplementary Materials: The following are available online at www.mdpi.com/2218-1989/8/1/15/s1, Figure
S1: Plasma extraction optimization: (a,c,e) summed sample signal and (b,d,f) average standard deviation in
relation to respective summed signal for the substance classes amino acids, organic acids, and sugars and
sugar alcohols for tested extraction methods (A—isopropanol/acetone 1:2, B—methanol, C—acetonitrile/H2O,
3:1, D—H2O/acetonitrile/methanol 1:2:2, E—methanol: H2O 5:1, F—acetonitrile, G—methanol/H2O, 8:1)
(blue—optimized, red—reference method); Figure S2: Enrichment patterns of additional plasma metabolites of S1,
S2, and S3: glycine (M2) and serine (M3) are derived from either starch or protein hydrolysis; glutamine (M5),
valine (M5), threonine (M4), isoleucine (M6), and tyrosine (M9) are derived from protein hydrolysis.
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